Lessons Learned From a Failed Anti-amyloid Trial for Alzheimer's Disease

    loading  Checking for direct PDF access through Ovid

Abstract

SYNOPSIS: Despite the disappointing results in EXPEDITION 3, modifications of clinical trials for Alzheimer's disease (AD) should be undertaken and trials targeting preclinical or early AD should continue with anti-amyloid agents.

SOURCE: Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med 2018;378:321-330.

Related Topics

    loading  Loading Related Articles